Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for urinary incontinence in overactive bladder
NCT01945489Phase 4Completed
- Sponsor
- Allergan
- Start
- Oct 2013
- Primary completion
- May 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) comparing OnabotulinumtoxinA with Placebo (2 arms). Primary endpoints: Percentage of Participants Who Achieve a 100% Reduction in Urinary Incontinence Episodes at 12 weeks and Change From Baseline in the Daily Average Number of Episodes of Urinary Incontinence at 12 weeks. Started Oct 2013; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT01945489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01945489.